Attached files
| file | filename |
|---|---|
| EX-99.1 - EX-99.1 - Zymeworks Inc. | d623070dex991.htm |
| 8-K - 8-K - Zymeworks Inc. | d623070d8k.htm |
Exhibit 99.2
Zymeworks Announces Election of Directors and Voting Results from Shareholder Meeting
Vancouver, Canada (May 6, 2021) – Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, is pleased to announce the detailed voting results on the items of business considered at its Annual General Meeting of Shareholders held on May 5, 2021 (the “Meeting”).
Shareholder Voting Results
The Shareholders voted on the following matters at this year’s Meeting.
Proposal 1 – Election of Directors
The nominees listed in Zymeworks’ proxy statement dated March 23, 2021 (the “Proxy Statement”) were elected as Directors of the Company. Detailed results of the votes are set out below:
| Proposal 1 |
Outcome of the Vote |
Votes by Ballot | ||||
| Election of Directors |
Votes For | Votes Withheld | ||||
| Susan Mahony |
Carried | 19,286,855 (71.48%) |
7,695,418 (28.52%) | |||
| Kelvin Neu |
Carried | 19,377,998 (71.82%) |
7,604,275 (28.18%) | |||
| Ali Tehrani |
Carried | 19,375,651 (71.81%) |
7,606,622 (28.19%) | |||
Proposal 2 – Advisory Vote on Executive Compensation
The Shareholders approved, on an advisory basis, the compensation of the Company’s named executive officers. Detailed results of the votes are set out below:
| Proposal 2 |
Outcome of the Vote
|
Votes by Ballot | ||||||
| Votes For | Votes Against | Votes Abstaining | ||||||
| Advisory Vote on Executive Compensation |
Carried | 24,095,093 (89.30%) |
2,607,651 (9.66%) |
279,529 (1.04%) | ||||
Proposal 3 – Appointment of Auditors
The vote was carried for the appointment of the Auditors, KPMG LLP. Detailed results of the votes are set out below:
| Proposal 3 |
Outcome of the Vote |
Votes by Ballot | ||||
| Votes For | Votes Withheld | |||||
| Appointment of KPMG LLP |
Carried | 28,930,162 (98.99%) |
296,499 (1.01%) | |||
Full details of all proposals are fully described in the Proxy Statement available on the Company’s profile on SEDAR at www.sedar.com, and on EDGAR at www.sec.gov, and the detailed results of voting on each proposal are included in the Report of Voting Results filed on SEDAR and on EDGAR.
About Zymeworks Inc.
Zymeworks is a clinical-stage biopharmaceutical company dedicated to the development of next-generation multifunctional biotherapeutics. Zymeworks’ suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of highly differentiated product candidates. Zymeworks’ lead clinical candidate, zanidatamab (ZW25), is a novel Azymetric™ bispecific antibody which has been granted Breakthrough Therapy designation by the FDA and is currently enrolling in a pivotal clinical trial for refractory HER2-amplified biliary tract cancer (HERIZON-BTC-01) as well as several Phase 2 clinical trials for HER2-expressing gastroesophageal and breast cancers. Zymeworks’ second clinical candidate, ZW49, is a novel bispecific HER2-targeting antibody-drug conjugate currently in Phase 1 clinical development and combines the unique design and antibody framework of zanidatamab with Zymeworks’ proprietary ZymeLink™ linker and cytotoxin. Zymeworks is also advancing a deep preclinical pipeline in oncology (including immuno-oncology agents) and other therapeutic areas. In addition, its therapeutic platforms are being leveraged through strategic partnerships with nine biopharmaceutical companies. For more information, visit www.zymeworks.com.
Contacts:
Investor Inquiries:
Ryan Dercho, Ph.D.
(604) 678-1388
ir@zymeworks.com
Jack Spinks
(604) 678-1388
ir@zymeworks.com
Media Inquiries:
Mary Klem
(604) 678-1388
media@zymeworks.com